AmoyDx
IPOPrecision oncology diagnostics for the world
Public · Xiamen, China · Founded 2008
- Headquarters
- Xiamen
- Employees
- 201–500
- Founded
- 2008
- Business Model
- B2B
- Website
- amoydx.com
- Type
- Public
About
AmoyDx (厦门艾德生物医药科技股份有限公司) was founded in 2008 by Professor Zheng Limou, a nationally recognized expert, focusing on molecular diagnostics in precision oncology. The company holds national enterprise technology center status and has proprietary technologies including ADx-ARMS®, Super-ARMS®, ddCapture®, and ADx-HANDLE®, with patents in China, the US, EU, and Japan. Products cover major cancer types; some products are approved in Japan and South Korea. AmoyDx is a strategic partner to AstraZeneca, Johnson & Johnson, Amgen, Eli Lilly, Merck, Eisai, Hengrui, and BeiGene for oncology drug development. GMP facilities hold NMPA and EU ISO13485 certifications. Tens of millions of cancer patients benefit annually.
Summary
AmoyDx is a Healthcare company based in Xiamen, China, founded in 2008.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Aug 2017
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...